Streptococcus pneumoniae is the most common cause of community-acquired pneumonia and empyema. Although the PCV7 has decreased the incidence of invasive pneumococcal disease, the vaccine's effectiveness in reducing empyema incidence is unclear, with conflicting regional reports.
Pneumonia is the most common cause of hospitalization of children in the United States. 1 Empyema is associated with 3% of all pneumonia hospitalizations 2 and up to one third of pneumococcal pneumonia hospitalizations. 3 Empyema causes significant morbidity, with prolonged hospitalizations [4] [5] [6] and multiple invasive procedures. 4, 5 Streptococcus pneumoniae is the most common organism responsible, causing 17% to 28% of bacterial pneumonia in the United States and up to 50% in developing countries. [7] [8] [9] In February 2000, the heptavalent pneumococcal conjugate vaccine (PCV7) was licensed in the United States. In October 2000, the Advisory Committee on Immunization Practices recommended PCV7 for all children Ͻ2 years of age. 9 PCV7 was designed to protect against the most common serotypes that cause invasive pneumococcal disease (IPD) (meningitis, bacteremia, and pneumonia) in children. 9, 10 Within 1 year after its introduction, the incidence of IPD had decreased across all age groups, [11] [12] [13] [14] including those for whom the vaccine is not recommended, such as infants too young to be vaccinated, 13 children Ͼ5 years of age, 11 and adults. 11, 14 Although PCV7 clearly reduced the incidence of IPD, its effect on empyema incidence was less clear. Studies of empyema incidence conducted after the introduction of PCV7 showed contradictory results: Empyema incidence was reported to have increased by 88% in Utah 15 and by 400% in California 16 but was shown to have decreased by 55% in Texas 17 and remained unchanged in Quebec, Canada. 18 These discrepancies highlight the limitations of regional studies. This study was designed to determine whether the incidence of empyema in children has changed since the introduction of PCV7 in the United States in 2000.
METHODS

Data Source
This study was a retrospective cohort analysis using administrative data from the Kids' Inpatient Database (KID) from 1997, 2000, 2003, and 2006 . 19 The KID is a national pediatric hospital discharge database developed by the Agency for Healthcare Research and Quality as part of the Healthcare Cost and Utilization Project and was designed to generate robust national estimates of pediatric hospitalizations. 19 The KID contains a random 10% sample of all uncomplicated births and 80% of all other hospitalizations for children aged 20 The KID contains discharge-level records of patient demographic information, diagnostic codes, procedure codes, and discharge disposition. No laboratory or physiologic patient data are included. Discharge weights provided with the KID were used to obtain national estimates. 20 The institutional review board at the University of California at Davis approved this study.
Patients
This study included children Յ18 years who were hospitalized in 1997, 2000, 2003, or 2006 . Exclusion criteria included patients (1) born during the hospital admission, (2) transferred from another hospital, (3) transferred from another facility (including a longterm care facility), (4) with a missing admission source, or (5) with a missing age.
Main Outcome
Children with empyema were identified by an International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code for empyema (510.0, 510.9) in any of the diagnoses on the discharge record. 21, 22 Codes for empyema cases related to tuberculosis (012.XX) were not counted.
Data Analysis
We estimated the total number of empyema-associated hospitalizations by year of admission, both overall and within strata defined by age group and gender. Point and variance estimates for these national estimates were calculated by using the Healthcare Cost and Utilization Project's weighting methodology, as implemented in the survey data analysis procedures in version 9.1.3 of SAS/Stat Software. 20 US Census estimates of the total number of children Յ18 years of age were used to convert estimated counts into hospitalization rates. 23 Hospitalization rates were expressed as the number of estimated hospitalizations per 100 000 children and were assumed to be approximately normally distributed for purposes of computing confidence intervals (CIs) and assessing the statistical significance of rate comparisons. Contrasts between prevaccine (1997) and transition-year (2000) or postvaccine (2003 and 2006) rates were adjusted for the survey design and were estimated both with and without adjustment for age. To explore whether PCV7 had a greater impact on the ages for which the vaccine was intended, we (1) examined whether the mean age of empyema hospitalization increased during the time period studied and (2) performed subgroup anal-yses restricted to children Ͻ5 years of age.
To investigate potential confounders associated with empyema incidence, we performed several additional analyses. To determine if an increase in incidence of empyema might be caused by misclassification, we examined the incidence of all complicated pneumonia in each time period. Children with complicated pneumonia were identified by ICD-9-CM codes for empyema, pleural effusion (511.1), or bacterial pneumonia (481-486) that required either chest tube placement (34.04) or a decortication procedure (34.51).
To determine if an increase in incidence of empyema might be caused by an increase in conditions that may lead to empyema, we examined the: (1) overall incidence of bacterial pneumonia and (2) incidence of microbiological causes of empyema. Because S pneumoniae and Staphylococcus aureus are the most common causes of empyema, 8, 17 we examined the incidence of both pneumococcal and S aureus empyema. Cases of empyema were attributed to pneumococcus if children with empyema had an additional ICD-9-CM code for pneumococcal pneumonia (481), pneumococcus (041.2), or pneumococcal septicemia (038.2). Empyema was attributed to S aureus if children with empyema had an additional ICD-9-CM code for S aureus pneumonia (482.41), S aureus (041.11), or S aureus septicemia (038.11).
In October 1997, the ICD-9-CM code for staphylococcal septicemia (038.1) was expanded to distinguish between S aureus septicemia (038.11), staphylococcal septicemia, and unspecified (038.10) and other (038.19) staphylococcal septicemia. 24 Similarly, in 1998, the ICD-9-CM coding for staphylococcal pneumonia (482.4) was expanded to distinguish between S aureus pneumonia (482.41), pneumonia caused by staphylococcus, and unspecified (482.40) and other (482.49) staphylococcal pneumonia. 24 Given the changes in ICD-9-CM coding, in case S pneumoniae and S aureus were miscoded as just streptococcus or staphylococcus, an additional sensitivity analysis was performed to examine the incidence of all streptococcus (481, 482. 
RESULTS
Overall
During 2006, a total of 2898 hospitalizations with empyema were estimated to have occurred among children Յ18 years of age in the United States ( Table  1 ). The empyema hospitalization rate was 3.7 per 100 000 children, an increase of 1.5 (70%) from the 1997 rate of 2.2 per 100 000. Unless otherwise indicated, the following estimates of hospitalizations and hospitalization rates are for the year 2006. All comparisons are between 1997 and 2006.
Age and Incidence
The mean age of children hospitalized for empyema in 2006 was 6.3 years (95% CI: 5.9 -6.6), 1 year younger than in 1997 (7.3 years [95% CI: 6.8 -7.8]). For children Ͻ5 years of age, 1541 (95% CI: 1306 -1776) empyemaassociated hospitalizations were estimated, representing 53% of empyema hospitalizations among children Յ18 years old. For children Ͻ5 years old, the empyema hospitalization rate increased 100%, from 3.8 (95% CI: 3.1-4.5) in 1997 to 7.6 (95% CI: 6.4 -8.7) per 100 000 children. Figure 1 shows that empyema hospitalization rates increased for children of all age groups (P Ͻ .01) except children 11 to 18 years of age (P ϭ .06), with the greatest increase in children 2 to 4 years of age (131%).
Complicated Pneumonias
In 2006, an estimated 4249 child hospitalizations were associated with complicated pneumonia, an increase of 45%, to 5.5 per 100 000 (Table 1) . Of the children with complicated pneumonia, 68% were coded as having empyema. Although the national incidence of pleural effusion decreased, the absolute decrease was only ϳ120 cases of pleural effusion, far fewer than the Ͼ1200 increase in empyema incidence over the same time period.
Bacterial Pneumonia and Microbiology
The overall incidence of bacterial pneumonia decreased 13%, to 244.3 per 100 000 ( S pneumoniae (2%), other streptococcus (1%; including streptococcus, unspecified), staphylococcus (2%), and mycoplasma (3%) were the most commonly identified bacterial causes of pneumonia. Between 1997 and 2006, of hospitalized children with pneumonia resulting from a specified organism, the percentage of pneumococcal pneumonia decreased from 21% to 14%; similarly, the percentage of streptococcal pneumonia decreased from 29% to 22%. The percentage of staphylococcal pneumonia increased from 12% to 16%, and the percentage attributed to other unspecified bacteria increased from 34% to 43%. The overall pneumococcal pneumonia hospitalization rate decreased 45%, to 4.9 per 100 000. There was no change in the overall staphylococcal pneumonia hospitalization rate (6.2 per 100 000).
The percentage of children hospitalized with bacterial pneumonia who had empyema increased 89%, from 0.8% in 1997 to 1.5% in 2006. The bacterial etiology was identified in 50% of empyema cases in 1997 and 43% in 2006. During this period, of children with empyema with a bacterial organism identified, the percentage of pneumococcal empyema decreased slightly, from 46% to 39%; similarly, the percentage of streptococcal empyema decreased from 66% to 56%. The percentage of staphylococcal empyema increased from 16% to 28%, and the percentage attributed to other unspecified bacteria was unchanged at ϳ15%. The incidence of pneumococcal empyema has not changed, with a hospitalization rate of 0.7 per 100 000. Children hospitalized with pneumococcal pneumonia were twice as likely to develop empyema in 2006 (13.7%) com- 
DISCUSSION
This study provides robust national estimates of hospitalizations associated with empyema among children in the United States. From 1997 to 2006, despite the introduction of PCV7, empyema hospitalization rates increased 70%. These increases occurred despite a decreasing incidence of bacterial pneumonia, pneumococcal pneumonia, and overall IPD, and a decreased mean age of children admitted with empyema. Specifically, we found a 45% decrease in incidence of pneumococcal pneumonia and no change in the incidence of pneumococcal empyema, making children with pneumococcal pneumonias twice as likely to have empyema in 2006 as in 1997. Our findings suggest that PCV7 is effective for preventing pneumonia but not effective for preventing empyema.
Before the introduction of PCV7, studies suggested that the incidence of empyema in children was increasing. 3, 17, [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] Our study showed that despite the introduction of PCV7, the incidence of empyema in children is continuing to increase. 15, 16 The 70% increase we found in our national population-based estimates of empyema incidence reconciles the previously discrepant single-institution and regional findings, [15] [16] [17] [18] which may have reflected regional microbiology or referral patterns.
We found the highest increase in empyema incidence in the youngest children (Ͻ5 years old), with the highest increase in children aged 2 to 4 years. Although it is not surprising that younger children had a greater incidence of empyema than older children because pneumococcal disease disproportionately affects younger children, 9 we do not know why children in the 2-to 4-year-old age group had a slightly higher increase in empyema incidence than the Ͻ2-year-old age group; this deserves additional study.
We found a slight decrease in overall bacterial pneumonia, driven by a 30% decrease in pneumonia in children Ͻ2 years old. These results are consistent with previous studies from which a 39% decrease in pneumonia in children Ͻ2 years old 35 and a trend toward a 40% decrease in pneumonia hospitalizations (including viral pneumonias) in children Ͻ1 year old. 36 Despite the dramatic decrease in pneumococcal pneumonia hospitalizations, we found no change in the incidence of pneumococcal empyema hospitalization. Our national results reconcile the previously discrepant regional findings, which may have reflected regional microbiology. 17, 31 Our results suggest that although PCV7 is effective against some serotypes responsible for pneumonia, it is not effective against serotypes responsible for empyema. PCV7 contains serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F. 9,10 Pneumococcal serotype 1 is responsible for only 4% to 7% of bacterial pneumonia, but is the most common cause of empyema (24%-50%) 3, 7, 28, 37 ; it is not included in PCV7. In addition, Utah's increased empyema incidence was attributed to pneumococcal serotypes 1, 3, and 19A. 15 Expanded-valency conjugate vaccines under development include a 10-valent vaccine, which additionally contains serotypes 1, 5, and 7F, and a 13-valent vaccine, which additionally contains serotypes 1, 3, 5, 6A, 7F, and 19A. That staphylococcus pneumonia incidence was unchanged but staphylococcus empyema incidence increased may be a result of increasing methicillin-resistant S aureus (MRSA). This theory is supported by a Texas study that revealed an increase in the proportion of empyema cases due to S aureus from 18% to 60%, with 78% being caused by MRSA. 17 The 50% decrease in IPD we report is consistent with the 29% to 69% decrease in IPD reported previously 11, 13 and a trend toward a 50% decrease in pneumococcal bacteremia reported in a smaller national hospital discharge survey study. 38 Our results are somewhat smaller than the 73% decrease in IPD in children Ͻ5 years old reported by the Active Bacterial Core Surveillance, 39, 40 which included laboratory data from both inpatient and outpatient sources, including children with occult pneumococcal bacteremia or pneumonia who may never be hospitalized.
There are some limitations in this study. Misclassification is possible in an administrative data set. Although pleural effusions may have been miscoded as empyema, the decreased number of pleural effusions (ϳ120) was not enough to account for the additional empyema cases (Ͼ1200). Complicated pneumonias (empyemas, pleural effusions, and pneumonias requiring chest tube or decortication) also increased, although it is possible that a temporal trend toward greater intervention for children with pneumonia might lead to bias. Because the KID does not include laboratory data such as culture results and serotyping, bacterial diagnosis must rely on coding. No studies have validated microbiology coding for children with pneumonia.
Our results, that 43% to 50% of children with empyema had a specific bacterial organism identified, are consistent with the 32% to 53% reported previously, which suggests that if specific organisms were identified, they were coded. 7, 9, 17, 28, 33, 41 Similarly, our finding that 14% of children with pneumonia had a bacterial etiology identified is consistent with the 6.5% reported in previous studies. 7 The increased incidence of culture-negative empyema is consistent with the results of previous studies 16, 17 and may be the result of increased antibiotic pretreatment. 16 This increased incidence of culture-negative empyemas may mean that we underestimated the actual increase in streptococcal empyema because previous molecular studies have found that 70% to 88% of culture-negative empyemas are caused by S pneumoniae, with 34% to 60% being serotype 1. 42, 43 The KID is only available every 3 years, which limits the ability to evaluate year-to-year variation. However, we were able to examine 4 years of data (1997, 2000, 2003, and 2006) , which show that empyema incidence has continued to increase. It is possible that changes from 1997 to 2006 in the set of states included in the KID to make it more nationally representative may have influenced the empyema rates reported.
Finally, the KID does not provide immunization status. We were unable to test whether children who received PCV7 were less likely to have IPD or empyema. However, in the United States, among children born in 2001, 89% received Ն1 dose and 68% received Ն3 doses of PCV7, and among children born in 2005, 95% received Ն1 dose and 84% received Ն3 doses of PCV7. 10 In addition, previous studies showed a decrease in IPD by 2001, 11 indicating that PCV7 was affecting IPD within 1 year of its introduction. Our study also revealed a decrease in IPD, indicating that although PCV7 is effective at preventing IPD, it is less effective at preventing empyema.
CONCLUSIONS
Despite the effectiveness of PCV7 in reducing pneumococcal meningitis, bacteremia, and pneumonia, the incidence of empyema has continued to increase. This is likely the result of serotype replacement with nonvaccine serotypes, 44 
